Methofill

Methotrexate, the active ingredient in Methofill, is an antimetabolite (folate antagonist) presented as a subcutaneous formulation for subcutaneous use. It is employed to treat autoimmune disorders such as rheumatoid arthritis and psoriasis, as well as certain cancers including acute lymphoblastic leukemia and non‑Hodgkin lymphoma. GNH USA supplies Methofill as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methofill, a folate antagonist, is used across several disease families where it modulates immune activity or inhibits malignant cell growth. - Rheumatoid arthritis: reduces disease activity and joint damage in adult patients. - Psoriasis: improves skin lesions and decreases severity. - Acute lymphoblastic leukemia: induces remission by targeting rapidly dividing lymphoblasts. - Non‑Hodgkin lymphoma: contributes to tumor control as part of combination regimens. - Other malignancies requiring antimetabolite therapy: provides cytotoxic effect in various solid and hematologic cancers.

Methofill may cause a range of adverse reactions, from mild to life‑threatening.

Common Side Effects: - Nausea and vomiting. - Fatigue or malaise. - Mucositis or oral ulceration. - Elevated liver enzymes. - Alopecia (hair loss). - Headache.

Serious or Rare Side Effects: - Bone marrow suppression leading to pancytopenia. - Severe hepatic toxicity or fibrosis. - Pulmonary fibrosis or interstitial pneumonitis. - Acute renal failure. - Life‑threatening infections. - Teratogenic effects causing fetal malformations.

Methofill requires careful monitoring and specific safety measures before and during therapy. - Pregnancy: contraindicated (Category X); avoid use in pregnant patients. - Renal function: assess baseline and monitor; adjust dose if impairment is present. - Liver function: regularly check hepatic enzymes and bilirubin. - Hematologic monitoring: perform complete blood counts to detect marrow suppression. - Infection risk: defer treatment in active infections and monitor for opportunistic infections. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methofill can interact with several drug classes, altering its safety profile.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Penicillins (e.g., ampicillin): reduce renal clearance, raising drug levels. - Alcohol: potentiates hepatotoxicity.

Moderate Interactions (Monitor Closely): - Sulfonamides: may increase methotrexate toxicity. - Trimethoprim‑sulfamethoxazole: similar risk of enhanced adverse effects.